Benzinga | Nov 8, 2021 06:34AM EST

SVB Leerink Maintains Outperform on Fate Therapeutics, Lowers Price Target to $115

SVB Leerink analyst Daina Graybosch maintains Fate Therapeutics (NASDAQ:FATE) with a Outperform and lowers the price target from $118 to $115.